Financial Times 20 May 2013
Actavis sought to fend off takeover threats by purchasing Dublin-based rival Warner Chilcott in a $5bn deal designed to turn it into the world’s third-largest generic drug company by sales.
The agreed all-stock deal, worth $8.5bn including net debt, follows recent efforts by competitors including Valeant and Mylan to acquire Actavis. Analysts said the move could spark alternative bids for Actavis or Warner Chilcott at a time of rapid consolidation in the sector.
Read more…
Actavis to acquire Warner Chilcott in $5bn pharmaceutical deal
